2026 POSTER PRESENTATIONS COMING IN FEBRUARY

Here is a reminder of the 2025 Poster Presentations:

P01: VZV Vaccine with Cap5 Showed Stronger Immune Response in Mice, Presented by May G., Areterna LLC

P02: NMR: A Powerful Tool for Oligonucleotide Therapeutics — From Synthesis to Structural Integrity, Presented by Jennifer S., Bruker BioSpin

P03: Oligonucleotide Manufacturing Innovation Centre of Excellence (OMICE), Presented by Grahame B., CPI

P04: Scalable, Automated Data Analysis Across RNA Therapeutics Assays, Presented by Ming W., Genedata AG

P05: High-Throughput Data Generation and Machine Learning Models for Enhanced mRNA Stability and Expression, Presented by Elise F., Ginkgo BioWorks, Inc.

P06: Prediction of Clinical Immunotoxicity of Oligonucleotide Therapeutics Using an Ex Vivo Test System with Circulating Human Whole Blood, Presented by Erika F., Immuneed AB

P07: BROTHERS: Enhancing the Safety and Efficacy of ASOs for Intractable CNS Diseases, Presented by Tsuyoshi Y., Liid Pharmaceuticals, Inc.

P08: Enhancing Extrahepatic Delivery of Oligonucleotides Using Bottlebrush Polymers, Presented by Ke Z., Northeastern University

P09: AI-Guided Enzyme Engineering for Oligonucleotide and Other Therapeutics, Presented by Lucas C., Pando Bioscience

P10: Mechanistic Characterization of Enhanced Delivery Oligonucleotide (EDO) Platform, Presented by Katherine W., PepGen, Inc.

P11: Development of Nav1.7 Channel Targeting Antisense Oligonucleotide as a Chronic Pain Therapeutic Using an Integrated Platform Based on Machine Learning and Optical Electrophysiology, Presented by Hongkang Z., Quiver Bioscience

P12: An Analytical Solution for Characterizing CRISPR-cas9 Cleavage and mRNA Capping Efficiency, Presented by Zhixiang L., Revvity

P13: Localization and Quantification of Oligonucleotide Therapeutic Drugs: Immunoassays Specific for Nucleic Acid Modifications Independent of Sequence, Presented by David C., Rockland Immunochemicals, Inc.

P14: Development of Purification Strategies for Plasmid DNA Template and mRNA Vaccine Production Using Sepax Bulk Media, Presented by Felder M., Sepax Bioscience, Inc.

P15: Purification of Oligonucleotide-Based Therapeutics Using Mixed-Mode Anion Exchange Chromatography, Presented by Felder M., Sepax Bioscience, Inc.

P16: Custom 5’-Triphosphate Oligonucleotides for Diagnostics and Gene Therapeutics, Presented by Xibo L., Synoligo Biotechnologies, Inc.

P17: A Novel Hybrid Biosensor for miRNA Detection Based on Peptide Nucleic Acids and Molecularly Imprinted Polymers, Presented by Muhammad A., Ulm University